Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524005 | 1.00 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ALDH1A1 | |
| Trifluoroacetamide SCHEMBL9181435 | 0.83 | NPC1 (0.47) | TAAR1SLC18A2SIGMAR1SLC6A4ADRB2 | |
| SCHEMBL178625 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL10076448 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL765297 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL7182179 | 0.80 | ALDH1A1 (0.50) | TAAR1SLC18A2SIGMAR1SLC6A4ALDH1A1 | |
| Methamphetamine SCHEMBL28275586 | 0.79 | NPC1 (0.68) | TAAR1SLC18A2SIGMAR1NPC1RAB9A | |
| Methamphetamine SCHEMBL28309635 | 0.79 | SIGMAR1 (0.68) | TAAR1SLC18A2SIGMAR1SLC6A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL23524368 | 0.78 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL7316113 | 0.78 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7956220-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956220-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2011-06-07 | — | — | US | disclosed |
| WO-2007005845-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-04 | — | — | US | disclosed |
| US-4960797-A | Improving mood element, stimulating sexual activity of aged people; free of side effects | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1990-10-02 | — | — | US | disclosed |
| EP-0186680-B1 | PHENYLISOPROPYLAMINE DERIVATIVE AND ITS PREPARATION | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1988-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | TAAR1 195/4885SLC18A2 676/4885SIGMAR1 1095/4885 |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | TAAR1 195/4885SLC18A2 676/4885SIGMAR1 1095/4885 |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | TAAR1 195/4885SLC18A2 676/4885SIGMAR1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.